Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 12 · below the Ichimoku cloud · RSI 43 · MACD below its signal · at its 52-week low
None of the 29 investors followed here reported a position in VDRM in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a VDRM trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -75.0 | 100.0 | -50.0 | −50.0% | ||
| 2025 | 62.2 | 8.5 | 43.6 | -34.8 | -91.8 | -70.0 | 100.0 | 66.7 | -80.0 | 0.0 | -50.0 | 100.0 | −97.3% |
| 2024 | -0.9 | 9.5 | 9.1 | -22.7 | -28.9 | -15.9 | -37.9 | 47.2 | -8.5 | 53.4 | 26.3 | -21.3 | −30.2% |
| 2023 | 6.5 | -18.9 | 371.0 | -55.4 | -5.3 | -6.1 | 4.0 | 6.1 | -0.3 | 9.1 | -10.0 | -1.9 | +71.0% |
| 2022 | 3.4 | -20.2 | 24.0 | -11.2 | -19.0 | -3.9 | 17.1 | 59.6 | -23.4 | -6.3 | -15.2 | -11.4 | −28.7% |
| 2021 | 869.5 | -16.2 | 1.6 | -2.2 | 104.7 | -14.0 | -17.0 | -30.3 | -10.9 | -1.0 | -2.1 | -37.9 | +341.6% |
| 2020 | 345.9 | -45.5 | -40.8 | -22.5 | -15.2 | 5.7 | 14.9 | 17.6 | -20.0 | 3.1 | -10.3 | 33.1 | +33.1% |
| 2019 | -20.7 | 4.3 | -8.3 | -4.5 | -28.6 | -3.3 | 51.7 | -1.4 | -30.9 | 0.0 | 13.3 | -12.9 | −49.0% |
| 2018 | 14.8 | -31.9 | 0.5 | -18.9 | -24.4 | -32.3 | -38.6 | 29.6 | -5.7 | -3.0 | -3.1 | -6.5 | −78.5% |
| 2017 | 212.0 | 396.0 | -25.3 | -50.0 | 72.3 | -27.7 | -16.7 | 29.5 | -15.6 | -12.8 | -18.2 | 15.4 | +440.0% |
| 2016 | -28.6 | 0.0 | 723.0 | -66.6 | -47.3 | -51.7 | 78.6 | -4.0 | -29.2 | 20.6 | 26.8 | -3.8 | −10.7% |
| 2015 | 21.4 | -40.0 | -44.1 | -40.4 | -55.9 | 300.0 | -23.3 | 0.0 | -13.0 | -17.5 | -39.4 | 40.0 | −80.0% |
| 2014 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -83.6 | -65.0 | 157.1 | -72.2 | -44.0 | −97.7% |
| 2013 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -33.3 | 0.0 | 0.0 | -87.8 | 0.0 | −91.9% |
| 2012 | -25.0 | 0.0 | -33.3 | 50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −25.0% |
| 2011 | -4.5 | -6.7 | -58.3 | -26.6 | -46.7 | 0.0 | 0.0 | -18.8 | -7.7 | 33.3 | 37.5 | -9.1 | −81.8% |
| 2010 | -25.0 | 0.0 | 0.0 | -16.7 | -44.0 | -9.5 | -34.2 | -12.0 | -8.2 | 49.5 | -17.2 | -12.0 | −81.7% |
| 2009 | 0.0 | 0.0 | 155.0 | 7.8 | 0.0 | 18.2 | -75.0 | 238.5 | -10.5 | 19.3 | -21.3 | 8.1 | +150.0% |
| 2008 | 0.0 | 0.0 | 0.0% |
No insider transactions reported for VDRM.
No analyst coverage for this instrument.
ViaDerma, Inc., through its subsidiary, manufactures and sells pharmaceutical related products in the United States. The company's lead product is Vitastem, a tetracycline and topical delivery technology for antibiotics to pain relief, skincare, and other. It is also developing various products for vitiligo, psoriasis, eczema, and other skin conditions using SkinPass topical delivery system, as well as antifungal, cosmetics, and pain management products. In addition, company develops anti-aging skin care, pain management, hair-loss, and toenail fungus products. It also provides licenses for its technology for pharmaceutical industry in various therapeutic areas. The company was formerly known as Décor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Las Vegas, Nevada.
No recent headlines.